The Efficacy and Safety of TAF vs Other NAs in Patients With LVL

  • End date
    Apr 30, 2024
  • participants needed
  • sponsor
    Third Affiliated Hospital, Sun Yat-Sen University
Updated on 25 January 2021
liver cancer
liver disease
hepatitis b antigen
chronic hepatitis


Patients with chronic hepatitis B should maximize the inhibition of HBV replication, which could reduce the incidence of liver cancer and liver disease-related complications. However, after 96 weeks of treatment with the first-line drugs, entecavir or tenofovir disoproxil fumarate, a certain proportion of patients still had low levels of HBV replication. Tenofovir alafenamide fumarate is a newly marketed anti-hepatitis B drug that is currently considered to be non-inferior to tenofovir disoproxil fumarate and safer bone and renal effects. Therefore, this research was put forward to investigate whether tenofovir alafenamide fumarate replacement for hepatitis B had a higher virological response rate and safety in patients with low levels of virus after 48 weeks of treatment with entecavir and tenofovir disoproxil fumarate.


Patients who meet the inclusion and exclusion criteria will be enrolled into the research. The participants will voluntarily choose to enter the experimental group or the control group with full informed consent. The control group will continue with the original regimen, while the study group will switch to tenofovir alafenamide fumarate antiviral therapy. Each group will enroll 100 participants.

Condition Hepatitis B, Hepatitis B, chronic hepatitis b, Cirrhosis Due to Hepatitis B
Treatment Tenofovir alafenamide Fumarate, Entecavir or Tenofovir disoproxil fumarate
Clinical Study IdentifierNCT04501224
SponsorThird Affiliated Hospital, Sun Yat-Sen University
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

HBsAg positive for over half a year
Age from 18 to 80 years old
Entecavir (0.5mg qd) or Tenofovir disoproxil fumarate (300mg qd) for 48 weeks or more
HBV DNA level was between 20IU/ ml-2000 IU /mL (COBAS, Taqman)

Exclusion Criteria

Low-level viremia of HBV caused by non-standard medication
serum total bilirubin is more than 2 times the upper limit of normal (ULN), or ALT or AST is more than 5ULN, or serum albumin is less than 30g/L
Overlap with HAV, HCV, HDV, HEV or HIV infection
Other liver disease: drug liver disease, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease, etc
Decompensated cirrhosis or liver cancer
Kidney damage, or autoimmune disease, or other organ failure
Combination of Entecavir or Tenofovir disoproxil fumarate
Interferon therapy within half a year
Entecavir (0.5mg qd) or Tenofovir disoproxil fumarate
Investigator considering inappropriate
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note